当前位置: X-MOL 学术J. Nanobiotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Journal of Nanobiotechnology ( IF 10.6 ) Pub Date : 2019-06-19 , DOI: 10.1186/s12951-019-0508-9
Chen Zhang , Doudou Zhang , Jian Liu , Jie Wang , Yusheng Lu , Junxia Zheng , Bifei Li , Lee Jia

Molybdenum disulfide (MoS2) has been widely explored for biomedical applications due to its brilliant photothermal conversion ability. In this paper, we report a novel multifunctional MoS2-based drug delivery system (MoS2-SS-HA). By decorating MoS2 nanosheets with hyaluronic acid (HA), these functionalized MoS2 nanosheets have been developed as a tumor-targeting chemotherapeutic nanocarrier for near-infrared (NIR) photothermal-triggered drug delivery, facilitating the combination of chemotherapy and photothermal therapy into one system for cancer therapy. The nanocomposites (MoS2-SS-HA) generated a uniform diameter (ca. 125 nm), exhibited great biocompatibility as well as high stability in physiological solutions, and could be loaded with the insoluble anti-cancer drug erlotinib (Er). The release of Er was greatly accelerated under near infrared laser (NIR) irradiation, showing that the composites can be used as responsive systems, with Er release controllable through NIR irradiation. MTT assays and confocal imaging results showed that the MoS2-based nanoplatform could selectively target and kill CD44-positive lung cancer cells, especially drug resistant cells (A549 and H1975). In vivo tumor ablation studies prove a better synergistic therapeutic effect of the joint treatment, compared with either chemotherapy or photothermal therapy alone. The functionalized MoS2 nanoplatform developed in this work could be a potent system for targeted drug delivery and synergistic chemo-photothermal cancer therapy.

中文翻译:

功能化的MoS 2-厄洛替尼在NIR下产生高热

由于其出色的光热转化能力,二硫化钼(MoS2)已在生物医学应用中得到了广泛的探索。在本文中,我们报告了一种新型的基于MoS2的多功能药物递送系统(MoS2-SS-HA)。通过用透明质酸(HA)装饰MoS2纳米片,这些功能化的MoS2纳米片已被开发为一种靶向肿瘤的化学治疗纳米载体,用于近红外(NIR)光热触发的药物递送,有助于将化学疗法和光热疗法组合成一个系统癌症治疗。纳米复合材料(MoS2-SS-HA)产生均一的直径(约125 nm),在生理溶液中显示出很大的生物相容性和高稳定性,并且可以负载不溶性抗癌药物厄洛替尼(Er)。在近红外激光(NIR)照射下,Er的释放被大大加速,这表明该复合材料可用作响应系统,通过NIR照射可控制Er的释放。MTT分析和共聚焦成像结果表明,基于MoS2的纳米平台可以选择性靶向并杀死CD44阳性肺癌细胞,尤其是耐药细胞(A549和H1975)。与单独的化学疗法或光热疗法相比,体内肿瘤消融研究证明联合治疗具有更好的协同治疗作用。在这项工作中开发的功能化的MoS2纳米平台可能是用于靶向药物递送和协同化学光热癌症治疗的有效系统。通过近红外辐射可以控制Er的释放。MTT分析和共聚焦成像结果表明,基于MoS2的纳米平台可以选择性靶向并杀死CD44阳性肺癌细胞,尤其是耐药细胞(A549和H1975)。与单独的化学疗法或光热疗法相比,体内肿瘤消融研究证明联合治疗具有更好的协同治疗作用。在这项工作中开发的功能化的MoS2纳米平台可能是用于靶向药物递送和协同化学光热癌症治疗的有效系统。通过近红外辐射可以控制Er的释放。MTT分析和共聚焦成像结果表明,基于MoS2的纳米平台可以选择性靶向并杀死CD44阳性肺癌细胞,尤其是耐药细胞(A549和H1975)。与单独的化学疗法或光热疗法相比,体内肿瘤消融研究证明联合治疗具有更好的协同治疗作用。在这项工作中开发的功能化的MoS2纳米平台可能是用于靶向药物递送和协同化学光热癌症治疗的有效系统。与单独的化学疗法或光热疗法相比,体内肿瘤消融研究证明联合治疗具有更好的协同治疗作用。在这项工作中开发的功能化的MoS2纳米平台可能是用于靶向药物递送和协同化学光热癌症治疗的有效系统。与单独的化学疗法或光热疗法相比,体内肿瘤消融研究证明联合治疗具有更好的协同治疗作用。在这项工作中开发的功能化的MoS2纳米平台可能是用于靶向药物递送和协同化学光热癌症治疗的有效系统。
更新日期:2019-06-19
down
wechat
bug